Argon supper-cryosurgery for patients with middle and late stage liver cancer

<正> OBJECTIVE: To assess the value of argon supper-cryosurgery for 42 patients with middle and late stageliver cancer.METHODS: Forty-two patients who had received argon supper-cryosurgery were analyzed retrospectivelyin terms of their clinical characteristics as well as the performance...

Full description

Saved in:
Bibliographic Details
Published in:Hepatobiliary & pancreatic diseases international 2003-08, Vol.2 (3), p.354-357
Main Authors: Dou, Ke-Feng, Yue, Shu-Qiang, Li, Hai-Ming, Yang, Yan-Ling, Tao, Kai-Shan, Guan, Wen-Xian, Chen, Yong, Sun, Kai
Format: Article
Language:English
Subjects:
Adult
Aged
Argon
cancer
complications
Cryosurgery - methods
Female
Humans
liver
Liver Neoplasms - mortality
Liver Neoplasms - surgery
Male
Middle Aged
operation
Postoperative Complications
Retrospective Studies
supper-cryosuygery
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<正> OBJECTIVE: To assess the value of argon supper-cryosurgery for 42 patients with middle and late stageliver cancer.METHODS: Forty-two patients who had received argon supper-cryosurgery were analyzed retrospectivelyin terms of their clinical characteristics as well as the performance of argon supper-cryosurgery.RESULTS: All patients were ameliorated in symptoms shortly after the operation, including painalleviation, psyche straightening up, alpha-fetoprotein descending or recovery. Jaundice occurred in 1patient and intraabdominal hemorrhage in 2. The levels of aspartate transaminase and alanine transaminasein all patients were elevated 1 month after the operation, and normalized after protective therapy of theliver. No operative death was noted.CONCLUSIONS: Cold and heat reversed therapy of argon supper-cryosurgery can drastically destroytumor tissue, especially the tumors which are too large to resect or close to the large vessels. It isapplicable to increase the operative rate, decrease the operative death rate, and enlarge the therapeuticscope.
ISSN:1499-3872